drugset / Trial / NCT01001338

Allopurinol Combination Study

NCT01001338

Phase 2 Completed 227 enrolled Ardea Biosciences, Inc.
RandomizedFactorialTriple-blindTreatment

Summary

To compare the proportion of subjects whose serum urate (sUA) levels are \< 6.0 mg/dL following 4 weeks of continuous treatment of RDEA594 in combination with allopurinol to allopurinol alone in subjects with documented inadequate hypouricemic response with standard doses of allopurinol.

Timeline

Start
2009-10
Primary completion
2011-01
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Lesinurad Small molecule 200 mg Oral
Subject Lesinurad Small molecule 400 mg Oral
Subject Lesinurad Small molecule 600 mg Oral
Background Allopurinol Small molecule

Indications